Mr. Slavin is the founding CEO of Fuzionaire and Fuzionaire Diagnostics. His mission is to create a better and more hopeful future. Through the work of Fuzionaire, he is leveraging the power of scientific breakthroughs to solve some of the world’s biggest challenges at scale. Outside of Fuzionaire, Mr. Slavin is the founder and chairman of the Slavin Family Foundation, whose fellowships support some of the world’s top student entrepreneurs, and the founder of EES Ventures, a seed-stage venture capital firm. With Nova Spivack, Mr. Slavin is also a co-founder of the Arch Mission Foundation (AMF), a nonprofit creating repositories of human knowledge and biology in space. AMF launched the first permanent library in solar orbit in February 2018 in the glove box of Elon Musk’s Tesla Roadster, which was the payload for SpaceX’s Falcon Heavy test flight. In 2019, AMF landed the Lunar Library on the Moon. Previously, Mr. Slavin spent six years at top-ranked law firm Skadden Arps, focusing on public and private mergers and acquisitions. He holds a BA from Yale, magna cum laude and Phi Beta Kappa, where he founded his first company and graduated at 19, and a JD from Harvard Law School.
Fuzionaire is a molecular science lab. We apply breakthrough discoveries in chemistry to improve the human condition.
Leveraging Earth-abundant, alkali metal catalysts and reagents, we drive new chemical transformations and amplify existing chemical processes. The new way in which we make and break bonds is more powerful, efficient, and clean than anything done today.
With core IP based on discoveries made at Caltech, in the laboratory of Nobel Prize winner Robert H. Grubbs, our applied research creates never-before-possible opportunities in medicine, energy, and materials.
Fuzionaire is led by a close-knit team of managers and world-class experts advising the company and its affiliates.
Nick SlavinCo-Founder and CEOFuzionaire
Anton Toutov PhDCo-FounderFuzionaire
Dr. Toutov holds a PhD in organic chemistry from Caltech in the laboratory of Nobel Laureate Robert H. Grubbs, where he held Dow-Resnick, NSERC, and Bristol-Myers Squibb fellowships. Dr. Toutov collectively has over 40 scholarly articles and patent grants and applications to his name spanning the fields of chemical synthesis, clean energy, and drug discovery. He is the recipient of the 2016 Demetriades Caltech Thesis Prize, the 2015 Alfred Bader Award for Student Innovation (Sigma-Aldrich Corporation), the 2014 Dow Chemical Sustainability Challenge Grand Prize, and the 2014 Milliken & Co. “Deep Science” award, among others. Dr. Toutov also serves as senior technical advisor to the Gates Foundation-backed Medicines for All Institute, improving access to affordable, high-quality medicines.
Mr. Spivack is a serial entrepreneur, technology futurist, and co-founder of the in house incubator of Stanford Research Institute (SRI) and Sarnoff Laboratories, which launched SIRI (acquired by Apple). He is the founder and CEO of the early stage science and technology incubator, Magical, and is co-founder and chairman of the Arch Mission Foundation. Previously, Mr. Spivack was CEO of Bottlenose, a leader in real-time data analytics. He founded Radar Networks in 2003, business incubator Lucid Ventures in 2001, and in 1994 he co-founded EarthWeb, Inc., one of the first web start-ups (record-breaking IPO in 1998) and spinout Dice.com (IPO in 2007). He is also a co-founder or early investor in The Daily Dot, Klout (acquired by Lithium), and a number of applied and life science companies including Space Adventures and Cambrian Genomics. Mr. Spivack is an inventor on nearly 100 granted and pending patents.
Bethany CatesDirector, Operations; SecretaryFuzionaire
Ms. Cates is Fuzionaire’s founding corporate secretary, director of operations, and executive assistant. Outside of Fuzionaire, she is executive director of the Slavin Family Foundation and director of operations of EES Ventures, a venture capital firm. Previously, Ms. Cates managed digital marketing and research at Austin-based communications strategy firm Influence Opinions, and held alumni relations and communications roles at The John Cooper School and Texas Exes, the University of Texas alumni association. Ms. Cates holds a BA from the University of Texas at Austin.
Ryan Clark PhDDirector, Discovery ChemistryFuzionaire
Dr. Clark is a medicinal chemist with experience leading multidisciplinary teams in the discovery of small molecule drug candidates. These novel compounds targeting enzymes, G protein-coupled receptors, nuclear hormone receptors, kinases and protein-protein interactions have spanned therapeutic areas including multiple sclerosis, oncology, virology, inflammation and fibrosis. Born out of careful multifactorial optimization and practical creativity, his discoveries have furthered the understanding of potential therapeutic targets and contributed to the advancement of multiple research programs. One of these discoveries, a first-in-class PPARα (peroxisome proliferator-activated receptor alpha) antagonist, is being evaluated in clinical trials to examine its impact on advanced-stage malignancies. Dr. Clark holds a PhD in chemistry from The Scripps Research Institute where he worked with Professor Dale Boger.
Sajjad "JJ" Ghobadi PhDDirector, Scientific PartnershipsFuzionaire
Dr. Ghobadi is a chemical engineer with experience in materials engineering, nanomaterials development, catalysis, and diagnostic imaging modalities. He is a first or contributing author of over 10 peer-reviewed publications and 50 international conference presentations, and in 2018 and 2019 was the recipient of consecutive research grants from industrial partners through the Center for Rational Catalyst Synthesis (a National Science Foundation Industry/University Cooperative Research Center). Dr. Ghobadi is a co-inventor of a novel rapid fluorination methodology (Fluorospray™) developed by Fuzionaire, and as a graduate student developed an award-winning point-of-care device for non-invasive melanoma diagnosis. He holds a PhD in chemical engineering from Virginia Commonwealth University, where he worked with Professor Frank Gupton.
Michael ScherrDirector, Strategy; Chief of StaffFuzionaire
Mr. Scherr is an entrepreneur with experience in operations and strategy. Prior to joining Fuzionaire, Mr. Scherr received a degree in History from Harvard College and spent two summers at Bridgewater Associates, helping to create their business intelligence group. While at Harvard, Mr. Scherr was Co-Founder and CEO of SafeSide Surgical, a medical safety platform that was acquired in 2020. He was also a member of the Korea Project Research Team at the Harvard Kennedy School, where he worked alongside practitioners to examine North Korean sanction evasion.
Thomas Singleton PhDDirector, Discovery ChemistryFuzionaire
Dr. Singleton received an Honours BSc from Trent University in 2009 and a PhD from McGill University in Materials Chemistry in 2015, and subsequently held postdoctoral fellowships at the University of Manchester developing molecular machine catalysts (2015 – 2017 Royal Society Newton International Fellow with Prof. Dave Leigh) and the Montreal Neurological Institute (2017 – 2021) developing novel radiotracers to expand the utility of PET scans. A co-inventor of two patents and co-author of 11 peer-reviewed publications, Dr. Singleton’s areas of experience include radiochemistry, materials, photochemistry and optics, and organic synthesis.
Takeo Morooka MD, MPHCo-FounderFuzionaire Radiosotope Technologies
Dr. Morooka is a seasoned physician executive with expertise in health policy and commercial diplomacy in healthcare. In recent years, he has founded several companies, including PH Consulting Ltd., a Tokyo based health policy and management advisory firm, and Japan Medical Isotope Technology Development K.K. (JAMIT), a radiopharmaceutical technology company. Previously, Dr. Morooka held managerial positions of increasing responsibility at organizations including MSD (known as Merck in the US and Canada), where he was Executive Director, Head of Health Policy; Covidien, where he was Vice President, Medical Affairs and Government Affairs; International University of Health and Welfare; World Health Organization; and Ministry of Health, Labour and Welfare of Japan. He earned his MD from Kyoto University and MPH from Harvard School of Public Health. Dr. Morooka has been registered to practice medicine in Japan since 1994 and is a plastic surgeon by training.
Alexey Fedorov PhDR&D Partner; Advisory BoardETH Zürich
Dr. Fedorov is Senior Scientist at the Laboratory of Energy Science and Engineering at the Institute of Energy Technology, Department of Mechanical and Process Engineering, of ETH Zürich. With experience in homogeneous and heterogeneous catalysis, spectroscopy, and high-throughput experimentation, Dr. Fedorov leads the ongoing collaborative research between Fuzionaire and ETH Zürich developing sulfur-free fuels, which is supported by Schmidt Futures. Previously, Dr. Fedorov was a postdoctoral fellow with Professor Christophe Copéret at ETH Zürich, with support from the Holcim Stifung, and Professor Robert H. Grubbs at Caltech, where his discovery of the strongly reducing properties of a potassium-based organosilane reagent was the launching point for further research at Caltech that led to Fuzionaire. Dr. Fedorov completed his undergraduate studies in chemistry at Saint Petersburg State University (Russia) in 2005 and received a PhD from ETH Zürich in 2010 for work on gas-phase ion-molecule reactions under the mentorship of Professor Peter Chen.
Fred Chin PhDAdvisory BoardStanford
Dr. Chin is Head of Cyclotron Radiochemistry and Assistant Professor of Radiology at Stanford University School of Medicine, where he researches and develops novel imaging agents and therapeutics with a focus on PET imaging. Closely linked with Stanford Health Care, Dr. Chin’s group provides more than 20 doses of 18F-FDG daily for standard-of-care PET imaging, and has brought or is in the process of bringing more than a dozen other tracers to the clinic. His group is involved in the arc of drug development, from research on the benchtop to translational first-in-human clinical studies, primarily using radiolabeled 18F and 11C tracers. Much of his interest lies in developing tracers to image the mysterious diseases of the brain (e.g., pain, addiction, Parkinson’s disease, Alzheimer’s disease, glioblastoma) or other cancers.
Jacob Hooker PhDAdvisory BoardHarvard Medical School
Dr. Hooker is a Professor of Radiology at Harvard Medical School and Director of Radiochemistry at the Martinos Center for Biomedical Imaging. He is also the Phyllis and Jerome Lyle Rappaport MGH Research Scholar and an Associate Neuroscientist at Massachusetts General Hospital, and an associate editor for ACS Chemical Neuroscience. Dr. Hooker’s lab has the mission of accelerating the study of the living human brain and nervous system through development and application of molecular imaging agents. The lab has developed and patented several imaging technologies for neuroscience, including a first-in-class radiotracer for neuroepigenetic imaging. Dr. Hooker was an inaugural recipient of the Talented 12 Award by C&E News, was named a Kavli Fellow by the National Academy of Sciences, has received a NARSAD Independent Investigator Award, and was awarded the Presidential Early Career Award for Scientists and Engineers by President Obama.
Dennis Liotta PhDAdvisory BoardEmory
Dr. Liotta is the Samuel Candler Dobbs Professor of Chemistry at Emory University and Executive Director of the Emory Institute for Drug Development. Through his discoveries, Dr. Liotta has helped to transform HIV/AIDS from a death sentence to a chronic infection. Over 90% of all of the HIV-infected persons in the United States have taken one of the drugs he invented. Dr. Liotta is an inventor on 75 issued US patents, many of which cover the antiviral and anticancer drugs and drug candidates he has discovered. He is the co-founder of numerous companies, two of which were acquired by Gilead Pharmaceuticals. He is recognized as one of the premier discoverers of novel therapeutics in the United States, having been an inventor of 10 FDA approved therapeutics including Epivir, Combivir, Trizivir, Epzicom, Epivir-HBV, Emtriva, Truvada, Atripla, Complera and Stribid.
Douglas Scherr MDAdvisory BoardWeill Cornell
Dr. Scherr is a Professor of Urology and the Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University. Dr. Scherr’s clinical focus is the treatment of urologic malignancies – in particular, the treatment of prostate cancer, bladder cancer, kidney cancer, and testicular cancers, as well as genitourinary and retroperitoneal sarcomas. He was the first physician at Cornell to perform a robotic prostatectomy, and travels nationally and internationally teaching the procedure to urologic surgeons. He has been active in the development of optical coherence tomography and its application to urologic imaging, and patented and developed the concept of “multiphoton endoscopy,” which utilizes high-speed laser energy to create high quality microscopic images of human tissue.
Kristin Swanson PhDAdvisory BoardMayo Clinic
Dr. Swanson is a Professor and Vice Chair for Research in the Department of Neurologic Surgery at Mayo Clinic. She is also Director of the Mathematical Neuro-Oncology Laboratory and Co-Director of the Precision Neurotherapeutics Innovation Program at Mayo Clinic. Dr. Swanson is a quantitative cancer researcher (mathematical oncologist) whose research lab has pioneered the burgeoning field of Mathematical Neuro-Oncology, developing patient-specific mathematical models of glioma to assess and predict disease course and optimize treatment. The lab works with clinical and research teams at Mayo Clinic to bring these innovations to the clinic while identifying new predictive models. Dr. Swanson’s research has been supported through funding by the NIH, numerous foundations, the James D. Murray Endowed Chair at the University of Washington, TGen, and the Mayo Clinic.
Christopher Waldmann PhDAdvisory BoardUniversity Medical Center Mainz
Dr. Waldmann is Head of Radiochemistry at the University Medical Center Mainz, Germany. He and his team provide the Department of Nuclear Medicine in Mainz as well as other healthcare institutions in the region with radiopharmaceuticals for PET imaging and therapeutic applications. As a postdoc at UCLA’s Crump Institute for Molecular Imaging, Dr. Waldmann played a central role in the original HetSiFA discovery work, in collaboration with the laboratory of Nobel Laureate Robert H. Grubbs at Caltech, that constitutes the scientific basis of Fuzionaire Diagnostics. At the Biomedical Cyclotron facility at UCLA, he was also involved in the production of PET radiopharmaceuticals for clinical trials. His radiochemical research focuses on the development and clinical implementation of fluorine-18 labeled radiopharmaceuticals for the noninvasive detection of cancer. Dr. Waldmann is author of a chapter in the textbook Molecular Imaging in Oncology, and his work has been published in leading academic journals including Theranostics, PNAS and Nature.